Compound 1 Modulates Opioid Receptors to Reduce Addiction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain relievers derived from opium, such as morphine and codeine, are associated with addiction and withdrawal symptoms, prompting the need for non-addictive alternatives that effectively manage pain without these side effects.
Innovation Solution
The development of compound 1, a pharmaceutical agent that modulates opioid receptors as a partial agonist at mu receptors, antagonist at kappa and ORL1 receptors, and antagonist at fentanyl-induced respiratory depression, offering a unique pharmacological profile for pain management without the addictive properties of traditional opioids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional opioid pain relievers (morphine, codeine) are used, then pain relief is achieved, but addiction and withdrawal symptoms occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of opioid compounds to create novel derivatives with altered receptor binding properties. Specifically, the invention changes the molecular parameters of opioid substances to achieve differential agonist/antagonist activity at mu, kappa, and delta receptors, thereby maintaining pain relief efficacy while reducing addictive potential through structural modification
Solution Approach 2:
The patent employs composite materials by creating hybrid opioid compounds that combine characteristics of both agonists and antagonists within a single molecular structure. These composite opioid molecules exhibit multi-receptor activity profiles, integrating beneficial pain-relieving properties while incorporating protective features that reduce addiction risk
2Object-generated harmful factors
If compound 1 is used to reduce addiction risk, then harmful effects are reduced, but the mechanism is complex involving multiple receptor interactions
Solution Approach 1:
The patent applies universality by designing compound 1 to simultaneously interact with multiple opioid receptor types (mu, kappa, and delta receptors) with different agonist/antagonist activities. This multi-functional approach allows a single compound to address multiple aspects of opioid pharmacology, reducing addiction risk through combined receptor modulation rather than relying on a single mechanism
Data Source
AI summary
The present disclosure is directed toward uses of compound 1 (or its stereoisomers) and compositions and/or dosage forms containing compound 1, wherein compound 1 is N-[2,5-dimethyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide.